|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Targeting L858R/T790M/C797S mutant EGFR is a major challenge in the new-generation EGFR tyrosine kinase inhibitors development for conquering drug resistant NSCLC.
|
31787359 |
2020 |
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
In this trial, we randomly assigned 556 patients with previously untreated advanced NSCLC with an <i>EGFR</i> mutation (exon 19 deletion or L858R allele) in a 1:1 ratio to receive either osimertinib (80 mg once daily) or one of two other EGFR-TKIs (gefitinib at a dose of 250 mg once daily or erlotinib at a dose of 150 mg once daily, with patients receiving these drugs combined in a single comparator group).
|
31751012 |
2020 |
|
Adenocarcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
EGFR L858R was more frequently harbored in the MP+ adenocarcinoma patients than in the MP- adenocarcinoma patients.
|
31732945 |
2020 |
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation
|
BEFREE |
Intense expression of L858R in the MP component was suggested, and the MP+ patients harboring L858R were at comparatively higher risk of recurrence in the group with pN0M0 lung adenocarcinoma.
|
31732945 |
2020 |
|
Hyperplastic Polyp
|
|
0.010 |
GeneticVariation
|
BEFREE |
Intense expression of L858R in the MP component was suggested, and the MP+ patients harboring L858R were at comparatively higher risk of recurrence in the group with pN0M0 lung adenocarcinoma.
|
31732945 |
2020 |
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Collectively, compound <b>13</b>, a novel hederagenin-NO donor hybrid with a different chemical structure from those of the current FDA-approved EGFR-targeted anti-NSCLC drugs, may be a promising lead compound for the treatment of NSCLC expressing gefitinib-resistant EGFR with a T790 M mutation or osimertinib-resistant EGFR-LTC with an L858R/T790M/C797S mutation.
|
31718182 |
2019 |
|
Lung Neoplasms
|
|
0.060 |
GeneticVariation
|
BEFREE |
The epidermal growth factor receptor (EGFR), when carrying an activating mutation like del19 or L858R, acts as an oncogenic driver in a subset of lung tumors.
|
31689114 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
EGFR)-targeted drugs have been the first-line treatment for patients with <i>EGFR</i>-mutant non-small cell lung cancer (NSCLC), especially exon 19 deletions and L858R mutation in exon 21.
|
31686847 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The MELROSE study, a French multicentric, open label, phase II trial (ClinicalTrials.govNCT03865511) plans to enroll 150 patients with treatment-naive advanced EGFR-mutated (L858R or exon 19 deletion) NSCLC, age ≥ 18 years, with an Eastern Cooperative Oncology Group performance status 0 or 1.
|
31648999 |
2020 |
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation
|
BEFREE |
ctDNA of EGFR-TKI sensitizing mutations (mEGFR), L858R substitution and Exon 19 deletion (E19d) mutation, was evaluated using droplet digital PCR (ddPCR) in 81 patients with lung adenocarcinoma which harbored mEGFR in the corresponding tumor tissues.
|
31647198 |
2019 |
|
Metastatic non-small cell lung cancer
|
|
0.100 |
GeneticVariation
|
BEFREE |
Eligible patients were aged 18 years or older (20 years or older in Japan and Taiwan) at the time of study entry, had stage IV NSCLC, with an EGFR exon 19 deletion (ex19del) or exon 21 substitution (Leu858Arg) mutation, an Eastern Cooperative Oncology Group performance status of 0 or 1, and no CNS metastases.
|
31591063 |
2019 |
|
CNS metastases
|
|
0.010 |
GeneticVariation
|
BEFREE |
Eligible patients were aged 18 years or older (20 years or older in Japan and Taiwan) at the time of study entry, had stage IV NSCLC, with an EGFR exon 19 deletion (ex19del) or exon 21 substitution (Leu858Arg) mutation, an Eastern Cooperative Oncology Group performance status of 0 or 1, and no CNS metastases.
|
31591063 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
We report three cases that were definitively diagnosed as LM from NSCLC with a mutation of epidermal growth factor receptor (<i>EGFR</i>) L858R.
|
31571928 |
2019 |
|
Metastatic Malignant Neoplasm to the Leptomeninges
|
|
0.030 |
GeneticVariation
|
BEFREE |
We report three cases that were definitively diagnosed as LM from NSCLC with a mutation of epidermal growth factor receptor (<i>EGFR</i>) L858R.
|
31571928 |
2019 |
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
The identification of activating mutations in the epidermal growth factor receptor (EGFR) gene (deletions in exon 19 [Del19] and point mutation L858R in exon 21) has been the first important step toward molecularly guided precision therapy in lung cancer.
|
31564835 |
2019 |
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
The identification of activating mutations in the epidermal growth factor receptor (EGFR) gene (deletions in exon 19 [Del19] and point mutation L858R in exon 21) has been the first important step toward molecularly guided precision therapy in lung cancer.
|
31564835 |
2019 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
The identification of activating mutations in the epidermal growth factor receptor (EGFR) gene (deletions in exon 19 [Del19] and point mutation L858R in exon 21) has been the first important step toward molecularly guided precision therapy in lung cancer.
|
31564835 |
2019 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
This uncertainty reflects the fact that most prospective clinical trials of EGFR TKIs have been restricted to patients with tumor harboring common (Del19 or L858R) mutations.
|
31558282 |
2019 |
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Electrochemical molecularly bioimprinted siloxane biosensor on the basis of core/shell silver nanoparticles/EGFR exon 21 L858R point mutant gene/siloxane film for ultra-sensing of Gemcitabine as a lung cancer chemotherapy medication.
|
31550632 |
2019 |
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Electrochemical molecularly bioimprinted siloxane biosensor on the basis of core/shell silver nanoparticles/EGFR exon 21 L858R point mutant gene/siloxane film for ultra-sensing of Gemcitabine as a lung cancer chemotherapy medication.
|
31550632 |
2019 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Electrochemical molecularly bioimprinted siloxane biosensor on the basis of core/shell silver nanoparticles/EGFR exon 21 L858R point mutant gene/siloxane film for ultra-sensing of Gemcitabine as a lung cancer chemotherapy medication.
|
31550632 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Prognostic value of EGFR 19-del and 21-L858R mutations in patients with non-small cell lung cancer.
|
31516600 |
2019 |
|
Metastatic non-small cell lung cancer
|
|
0.100 |
GeneticVariation
|
BEFREE |
A 66-year-old man was diagnosed with relapsed stage IV non-small cell lung cancer with an EGFR mutation in exon 21 (L858R) 2 years after stereotactic body radiotherapy.
|
31486987 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
In the entire assessable population of 4465 EGFR-mutant NSCLC patients, significant interactions with PFS were found for gender (males vs. females; pooled ratio of the PFS-HRs = 1.2; 95% CI 1.12-1.56), smoking history (smokers vs. non-smokers; pooled ratio of the PFS-HRs = 1.26; 95% CI 1.05-1.51), and type of EGFR mutation (patients with exon 21 L858R mutation vs. exon 19 deletion; pooled ratio of the PFS-HRs = 1.39; 95% CI 1.18-1.63).
|
31466227 |
2019 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
T790M coexisted with L858R mutation (8/11) more than with deletions in exon 19 (19del) mutation (3/11) in TKI-naive tumors, while 19del co-occurred as often as L858R in post-TKI tumors.
|
31463130 |
2019 |